Our Mission

De Facto Diagnostics is dedicated to advancing transplantation research through innovative technologies that empower researchers, support scientific discovery, and address the evolving needs of laboratories.

Explore Products

Leadership & Scientific Collaboration

Paul Tausch

Co-Founder, De Facto Diagnostics

De Facto Diagnostics was founded by Paul and Kim Tausch, united by a shared passion for advancing transplantation research.

Paul brings more than four decades of experience in transplant diagnostics, with a career spanning One Lambda, Thermo Fisher Scientific's Transplant Diagnostics business, and most recently CareDx.

His experience throughout the evolution of the field has shaped the company's vision for developing innovative technologies that address the needs of today's researchers while anticipating the challenges of tomorrow.

De Facto Diagnostics builds on this foundation by collaborating with experts who share a commitment to scientific innovation and advancing transplantation research.

Curt Lind

Founder, Heirloom Diagnostics, LLC
Chief Scientific Advisor, De Facto Diagnostics

Curt Lind, Founder of Heirloom Diagnostics, LLC, serves as Chief Scientific Advisor to De Facto Diagnostics.

Paul and Curt have worked together and collaborated in many capacities for more than 25 years, building a longstanding professional relationship grounded in their shared understanding of transplant diagnostics and vision for the field's future.

Their combined experience and commitment to innovation form the foundation of an exclusive collaboration between the two companies, focused on developing technologies for transplantation research.

Together, De Facto and Heirloom are dedicated to developing innovative technologies that expand research capabilities and create new opportunities for discovery in HLA and transplantation research.

De Facto Diagnostics and Heirloom Diagnostics share a vision for the future of transplantation research—and a commitment to helping move the field forward.